Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma.

scientific article published on 19 April 2018

Anti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1172/JCI.INSIGHT.120505
P932PMC publication ID5931130
P698PubMed publication ID29669947

P50authorCarl H. JuneQ19277113
Alfred L GarfallQ80726281
Edward A. StadtmauerQ85544110
Megan M. DavisQ85544115
Irina KulikovskayaQ85544118
Anne LamontagneQ85544147
Donald L. SiegelQ85544150
Bruce L. LevineQ85544154
Regina M. YoungQ85544157
Michael C MiloneQ88137713
Emily C AyersQ89776169
Jan MelenhorstQ90374440
Martin CarrollQ92827331
Brendan M WeissQ95945848
Kavita DhodapkarQ98394175
Naseem D S KerrQ117283215
Karen DengelQ117283217
Maria KrevvataQ117283232
Selene Nunez-CruzQ117283233
Marcela V. MausQ38321614
William MatsuiQ38326712
Dan T VoglQ42576934
Simon F LaceyQ56978267
Adam D CohenQ63987185
P2093author name stringQiuju Wang
Rituparna Das
Patricia A Mangan
Wei-Ting Hwang
Madhav V Dhodapkar
P2860cites workCore transcriptional regulatory circuitry in human embryonic stem cellsQ24322016
Characterization of clonogenic multiple myeloma cellsQ24610291
Clonogenic multiple myeloma progenitors, stem cell properties, and drug resistanceQ24644883
Chimeric antigen receptor T cells for sustained remissions in leukemiaQ29617588
Salvage second hematopoietic cell transplantation in myelomaQ30416452
Identification of translocation products but not K-RAS mutations in memory B cells from patients with multiple myelomaQ33590627
Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells.Q33687086
Differentiation stage of myeloma plasma cells: biological and clinical significance.Q33712516
NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma.Q34485950
International uniform response criteria for multiple myeloma.Q34549410
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma.Q34557946
Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial.Q34568939
Hedgehog signaling maintains a tumor stem cell compartment in multiple myelomaQ35652021
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myelomaQ36206430
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathyQ36229280
Chimeric Antigen Receptor T Cells against CD19 for Multiple MyelomaQ36284584
Prospective analysis of antigen-specific immunity, stem-cell antigens, and immune checkpoints in monoclonal gammopathyQ36322760
The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cellQ36362222
Stemness of B-cell progenitors in multiple myeloma bone marrowQ36405908
Metastatic Latency and Immune Evasion through Autocrine Inhibition of WNT.Q36731080
A monoclonal gammopathy precedes multiple myeloma in most patientsQ37209020
The multiple roles for Sox2 in stem cell maintenance and tumorigenesisQ37411246
Frequency and kinetics of polyclonal and clonal B cells in the peripheral blood of patients being treated for multiple myelomaQ73281262
Myeloma progenitors in the blood of patients with aggressive or minimal disease: engraftment and self-renewal of primary human myeloma in the bone marrow of NOD SCID miceQ73386754
Levels of circulating CD19+ cells in patients with multiple myelomaQ74160384
Leukemic B cells clonally identical to myeloma plasma cells are myelomagenic in NOD/SCID miceQ77738087
Clonotypic myeloma cells able to xenograft myeloma to nonobese diabetic severe combined immunodeficient mice copurify with CD34 (+) hematopoietic progenitorsQ78358421
Extramedullary vs medullary relapse after autologous or allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) and its correlation to clinical outcomeQ80937605
Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patientsQ82242208
CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patientsQ83696156
Growth differentiating factor 15 enhances the tumor-initiating and self-renewal potential of multiple myeloma cells.Q37535244
Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.Q37599478
Flow cytometric differentiation of abnormal and normal plasma cells in the bone marrow in patients with multiple myeloma and its precursor diseasesQ37626783
Myeloma stem cell concepts, heterogeneity and plasticity of multiple myeloma.Q38151195
Multiple Myeloma Includes Phenotypically Defined Subsets of Clonotypic CD20+ B Cells that Persist During Treatment with RituximabQ38260684
Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working GroupQ39214847
Patients with multiple myeloma develop SOX2-specific autoantibodies after allogeneic stem cell transplantationQ39424061
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myelomaQ40096913
Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemiaQ41429394
In multiple myeloma, clonotypic B lymphocytes are detectable among CD19+ peripheral blood cells expressing CD38, CD56, and monotypic Ig light chainQ42674911
Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myelomaQ42762683
Extramedullary relapses after allogeneic non-myeloablative stem cell transplantation in multiple myeloma patients do not negatively affect treatment outcome.Q43880095
Molecular remission of CML after autotransplantation followed by adoptive transfer of costimulated autologous T cellsQ44632359
Targeting CD138-/CD20+ Clonogenic Myeloma Precursor Cells Decreases These Cells and Induces Transferable Antimyeloma Immunity.Q45026469
Clinical drug resistance linked to interconvertible phenotypic and functional states of tumor-propagating cells in multiple myeloma.Q46027082
Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcomeQ46916861
Cancer stem cells revisitedQ49557760
Two States of Myeloma Stem CellsQ50077900
SOX2 controls tumour initiation and cancer stem-cell functions in squamous-cell carcinomaQ50454918
Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer.Q51987984
Isolated Extramedullary Relapse of Acute Leukemia after Allogeneic Stem Cell Transplantation: Different Kinetics and Better Prognosis than Systemic Relapse.Q52777420
Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage.Q52868194
CD19-CD45 low/- CD38 high/CD138+ plasma cells enrich for human tumorigenic myeloma cells.Q53370464
A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction.Q54122476
Circulating monoclonal B cells expressing P glycoprotein may be a reservoir of multidrug-resistant disease in multiple myeloma.Q54216497
Multiple Myeloma: Diagnosis and Treatment.Q55119496
In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of diseaseQ56991213
Donor T-cell responses and disease progression patterns of multiple myelomaQ57560891
Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profileQ60203403
Circulating monotypic B-cells in multiple myeloma: association with lambda paraproteinsQ69218609
Circulating clonal lymphocytes in myeloma constitute a minor subpopulation of B cellsQ71087704
The blood B-cells and bone marrow plasma cells in patients with multiple myeloma share identical IgH rearrangementsQ71682102
The proliferative potential of myeloma plasma cells manifest in the SCID-hu hostQ73160451
P433issue8
P577publication date2018-04-19
P1433published inJCI insightQ27727187
P1476titleAnti-CD19 CAR T cells with high-dose melphalan and autologous stem cell transplantation for refractory multiple myeloma
P478volume3